Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Revised Hospital Accreditation Standards in Lebanon- December 2022

 
The health care system has been adversely impacted by multi-dimensional crisis, including the economic collapse, COVID-19 pandemic, Beirut Port explosion, and socio-political unrest. The unavailability and increased cost of basic commodities such as fuel and electricity has further challenged an overburdened system.

Maintaining the quality of care and patient safety in the midst of the challenges facing health institutions remains a priority and constitutes a guarantee for quality services. Maintaining quality standards saves lives, contributes to alleviating the financial burden, and reserves the position of high-level health services on the health map in the region.

After a long period of pausing the Accreditation process in Lebanon, the Ministry of Public Health is working again to revive this very important project that has started since 2001 and was updated and improved over time.  For the purpose of improving and updating the current hospital accreditation system in Lebanon, the Ministry of Public Health aimed to revise and develop new Lebanese hospital accreditation standards according to latest evidence and international best practices, in compliance with International Society for Quality in Healthcare (ISQua) requirements.

Since January 2022, and under the great support of AFD (Agence Française de Développement), a cooperation agreement was signed between the Lebanese Ministry of Public Health (MOPH) and the French Health Authority (HAS) for a new iteration of the accreditation project in collaboration, in collaboration with the Ecole Supérieure des Affaires (ESA) as a local counterpart to ensure logistical, educational and administrative support. The governance of the program kept the current organizational structure: the Comité National d’Accréditation Hospitalière (CNAH) and the Comité Technique d’Accréditation Hospitalière (CTAH). In addition to a new unit created at the Ministry of Health as the operational structure, the Bureau d’Accréditation et d’Evaluation (BAE) to follow-up on the implementation of the project. The revision of the procedure and the manual was performed by local and international experts.

The Ministry of Public Health announces the official publication of the new accreditation standards manual for hospitals. The present version has been updated to include “intent”  sections for each standard, aiming at allowing hospitals better comprehend and meet the requirements of the standards.

For any inquiry, please contact the Accreditation office at the MOPH by email on:
accreditation@moph.gov.lb or ritafreiha@hotmail.com
 
    ...
    62
    ...
ATC Name B/G Ingredients Dosage Form Price
L02BB06 NUBEQA B Darolutamide - 300mg Tablet, film coated 452,633,527 L.L
L02BB05 ERLEADA B Apalutamide - 60mg 60mg Tablet, film coated 254,089,146 L.L
L02BB05 ERLEADA B Apalutamide - 60mg 60mg Tablet, film coated 254,089,146 L.L
L02BB04 XTANDI B Enzalutamide - 40mg 40mg Capsule, soft 267,649,535 L.L
L02BB04 ENZASTIK 40 G Enzalutamide - 40mg 40mg Capsule 82,838,963 L.L
L02BB03 CASODEX B Bicalutamide - 50mg 50mg Tablet, film coated 3,777,541 L.L
L02BB03 BICALUTAMIDE ACCORD G Bicalutamide - 50mg 50mg Tablet, film coated 1,382,814 L.L
L02BB03 BICALUTAMIDE BIOGARAN G Bicalutamide - 50mg 50mg Tablet, coated 4,315,078 L.L
L02BB03 BICALUTAMIDE GP PHARM G Bicalutamide - 50mg 50mg Tablet, film coated 1,306,215 L.L
L02BB03 BICAMIDE G Bicalutamide - 50mg 50mg Tablet, film coated 1,451,753 L.L
L02BB03 PROSMIDE G Bicalutamide - 50mg 50mg Tablet, film coated 3,597,914 L.L
L02BB03 CASODEX B Bicalutamide - 150mg 150mg Tablet, film coated 10,863,782 L.L
L02BA03 FASLODEX B Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution L.L
L02BA03 FASLODEX B Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution 46,628,557 L.L
L02BA03 FLUVESTRANT ARROW G Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution 12,162,315 L.L
L02BA03 FULVESTRANT EVER PHARMA G Fulvestrant - 250mg/5ml 250mg Injectable solution 28,766,788 L.L
L02BA03 FUXRAN G Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution 37,882,154 L.L
L02BA01 TAMOXIFENE BIOGARAN G Tamoxifen (citrate) - 10mg 10mg Tablet 415,247 L.L
L02BA01 TAMOXIFEN SANDOZ G Tamoxifen (citrate) - 20mg 20mg Tablet, film coated 497,222 L.L
L02BA01 TAMOXIFENE BIOGARAN G Tamoxifen (citrate) - 20mg 20mg Tablet 858,715 L.L
L02AE04 DECAPEPTYL B Triptorelin - 0.1mg 0.1mg Injectable lyophilised powder for solution+diluent 2,366,507 L.L
L02AE04 DECAPEPTYL LP B Triptorelin (pamoate) - 3mg 3mg Injectable powder for suspension+diluent 11,778,312 L.L
L02AE04 DECAPEPTYL LP B Triptorelin (pamoate) - 11.25mg 11.25mg Injectable powder for suspension+diluent 31,761,098 L.L
L02AE04 GONAPEPTYL B Triptorelin acetate - 0.1mg 0.1mg Injectable solution 4,637,600 L.L
L02AE04 GONAPEPTYL CR B Triptorelin - 3.75mg 3.75mg Injectable powder for suspension+diluent 12,095,730 L.L
L02AE03 ZOLADEX LA B Goserelin (acetate) - 10.8mg 10.8mg Injectable suspension L.L
L02AE03 ZOLADEX DEPOT B Goserelin (acetate) - 3.6mg 3.6mg Injectable suspension 8,820,074 L.L
L02AE03 ZOLADEX LA B Goserelin (acetate) - 10.8mg 10.8mg Injectable suspension 35,121,328 L.L
L01XY02 PHESGO BioTech Pertuzumab - 600mg, Trastuzumab - 600mg Injectable solution 326,054,156 L.L
L01XY02 PHESGO BioTech Pertuzumab - 1200mg, Trastuzumab - 600mg Injectable solution 591,417,874 L.L
    ...
    62
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025